Actionable news
0
All posts from Actionable news
Actionable news in ACAD: ACADIA Pharmaceuticals Inc.,

Acadia Pharmaceuticals And The Baker Brothers

Summary

ACAD is most famously known for their drug Nuplazid, for the treatment of Parkinson Disease Psychosis (PDP).

Many investors know the largest shareholders in the Company are the Bakers Brother and Fidelity.

What I think most investors do not realize is how drastically this company has been reshaped since March of 2015, the time of the last NDA delay.

Yesterday, I wrote a piece on Acadia Pharmaceuticals (NASDAQ:ACAD) and my view on where the shorts went wrong. ACAD is most famously known for their drug Nuplazid, for the treatment of Parkinson Disease Psychosis (NYSEARCA:PDP), approved at the end of April. Nuplazid, a 5-HT2A inverse agonist, is the first drug of its kind and the only drug approved to treat PDP. Most of this is nothing new to many investors who like me are invested in ACAD. What I think most investors do not realize is how drastically this company has been reshaped since March of 2015, the time of the last NDA delay.

Many investors know the largest shareholders in the Company are the Bakers Brother and Fidelity. Combined the two investment firms own about 41.1 million shares or nearly 47% of the outstanding 88 million share float. However, the Bakers driving this company forward

When I presented ACAD as my best idea for 2016 at the Idea Generation Conference hosted By the Kaufman Brother on March 2nd, I decided to explore the current construction of the board and upper management. Below are my findings.

Hires as of the beginning of March 2016 to the company included:

Srdjan (Serge) Stankovic, M.D., M.S.P.H., - EVP, Head of R&D:...


More